Rigel Publishes Data On REZLIDHIA In Post-Venetoclax Patients With Mutant IDH1 AML In Leukemia & Lymphoma
Portfolio Pulse from Benzinga Newsdesk
Rigel Pharmaceuticals published data on REZLIDHIA (olutasidenib) showing a 43.8% durable composite complete remission rate in post-venetoclax patients with mutant IDH1 AML. The safety profile was consistent with previous findings, suggesting olutasidenib could be a valuable treatment option for this patient group.
April 04, 2024 | 12:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Rigel Pharmaceuticals' publication of positive data on REZLIDHIA for mutant IDH1 AML patients previously treated with venetoclax could positively impact investor sentiment and the stock price in the short term.
The publication of positive clinical trial results typically leads to increased investor confidence, which can positively impact the stock price. Given the specificity of the data to Rigel's product and its potential market impact, this news is highly relevant and important to RIGL investors.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100